The half-life of aspirin in the human body is only 15–20 min; therefore, the clinical observations (Bosetti et al, 2006; Chan et al, 2009) that once-daily administrations of aspirin appear to have an anti-cancer effect, particularly in tumours that overexpress Cox-2 are intriguing. This evidence concerns the gene PTGS2 and neoplasm.